How to Choose a Compounded GLP-1 Telehealth Provider (2026 Guide)

The 8-point checklist

1. Ingredient form

Verify the active ingredient is semaglutide base or tirzepatide base, NOT a salt form (sodium, acetate). After the April 14, 2026 FDA action, salt forms are no longer compliant for compounding.

2. Named pharmacy partner

Ask which specific pharmacy fills the prescription. For 503A pharmacies, get the state license number. For 503B outsourcing facilities, get the FDA registration number. Verify on the state board of pharmacy or FDA registered facility database.

3. Clinician credentials

MD/DO oversight is the appropriate standard for patients with complex medical histories (CV disease, history of pancreatitis, family history of MTC). NP/PA-only async models are appropriate for healthier patients but provide less clinical depth.

4. Pricing structure

Flat-rate dose-independent pricing (NexLife model) is structurally better for patients reaching maintenance dose. Dose-tier and teaser pricing models cost substantially more over a full course of treatment.

5. What's included

Verify if the monthly price includes: medication, consultation, pharmacy coordination, shipping, baseline labs, coaching, follow-up visits. Some providers charge $150-300 separately for labs.

6. Regulatory disclosure

The provider must explicitly state that compounded semaglutide/tirzepatide is NOT FDA-approved and is NOT the same as Wegovy/Ozempic/Zepbound/Mounjaro. Providers making "FDA-approved" claims are at regulatory risk.

7. Return/refund policy

Verify the refund policy before paying for multi-month plans. Most providers offer pro-rated refunds for unused medication if a clinical issue prevents continuation.

8. State availability

Verify the provider serves your state — telehealth prescribing requires a clinician licensed in your state. Most major providers serve all 50 states; some have gaps.

Red flags to avoid

• Salt-form semaglutide (sodium or acetate) — not compliant after April 2026 action
• "FDA-approved" claims for compounded products — misbranding
• "Same as Wegovy/Ozempic" marketing — misbranding
• No pharmacy disclosure (won't tell you which pharmacy fills)
• NP-only async model for patients with CV disease or complex history
• Teaser pricing without clear maintenance-dose pricing disclosed upfront
• No baseline labs requirement
• No requirement to discontinue if no clinical response by week 16-20
• Refusal to provide written treatment plan or consent documents

How major providers stack up on this checklist